New and Emerging Treatments for Rosacea

Authors

Lauren M. Gold, Henry Ford Health
Zoe D. Draelos

Recommended Citation

Gold LM, Draelos ZD. New and Emerging Treatments for Rosacea. American journal of clinical dermatology 2015; 16(6):457-461.

Document Type

Article

Publication Date

12-1-2015

Publication Title

American journal of clinical dermatology

Abstract

Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews new treatment options including ivermectin, brimonidine, the new foam formulation of azelaic acid, and oxymetazoline. The potential role in therapy, patient selection, and adverse effects of these agents are discussed.

Medical Subject Headings

Administration, Topical; Brimonidine Tartrate; Clinical Trials, Phase III as Topic; Dermatologic Agents; Dicarboxylic Acids; Drug Approval; Female; Follow-Up Studies; Forecasting; Humans; Ivermectin; Male; Oxymetazoline; Patient Satisfaction; Rosacea; Severity of Illness Index; Treatment Outcome; United States; United States Food and Drug Administration

PubMed ID

26396117

Volume

16

Issue

6

First Page

457

Last Page

461